Equities research analysts expect that Endocyte, Inc. (NASDAQ:ECYT) will announce earnings of ($0.16) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Endocyte’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.16). Endocyte posted earnings per share of ($0.26) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.5%. The business is expected to announce its next quarterly earnings results on Friday, March 9th.
According to Zacks, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts forecast that the company will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Endocyte.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The firm had revenue of $0.03 million during the quarter. During the same quarter last year, the company earned ($0.21) earnings per share. Endocyte’s revenue for the quarter was up .0% on a year-over-year basis.
Endocyte (NASDAQ ECYT) traded up $0.10 during trading hours on Friday, hitting $4.91. The company had a trading volume of 658,000 shares, compared to its average volume of 1,176,872. Endocyte has a twelve month low of $1.17 and a twelve month high of $6.55.
In other news, VP Christopher P. Leamon sold 23,231 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.04, for a total transaction of $117,084.24. Following the completion of the sale, the vice president now owns 150,579 shares in the company, valued at $758,918.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Philip S. Low acquired 5,600 shares of Endocyte stock in a transaction dated Monday, November 13th. The shares were purchased at an average price of $4.84 per share, with a total value of $27,104.00. Following the acquisition, the insider now owns 283,005 shares of the company’s stock, valued at $1,369,744.20. The disclosure for this purchase can be found here. 14.86% of the stock is owned by insiders.
Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its holdings in shares of Endocyte by 1,064.3% during the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after acquiring an additional 393,975 shares during the period. FMR LLC boosted its stake in shares of Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after buying an additional 31,168 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Endocyte by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 6,469 shares during the period. Spark Investment Management LLC bought a new stake in shares of Endocyte in the second quarter valued at approximately $177,000. Finally, LMR Partners LLP bought a new stake in shares of Endocyte in the second quarter valued at approximately $196,000. Institutional investors own 17.68% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Week Herald and is owned by of Week Herald. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://weekherald.com/2017/12/15/zacks-analysts-expect-endocyte-inc-ecyt-will-post-earnings-of-0-16-per-share.html.
Endocyte Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.